Key result
mRNA vaccines show ~95% efficacy in preventing COVID-19 with a favorable safety profile.
Why the study?
The rapid development and promise of mRNA vaccines against SARS-CoV-2 prompted an examination of their design principles, mechanisms, and pre-clinical and clinical trial data.
This review provides a comprehensive overview of the rapid development, design principles, and clinical trial status of mRNA vaccines for COVID-19.
No takes yet. Share an insight, caveat, or question.
Supports mRNA vaccine strategies in COVID-19; leaves open durability, variant adaptation, and real-world validation questions.
Park et al. (2021) conducted a review in COVID-19. mRNA vaccines was evaluated. mRNA vaccines, including mRNA-1273 and BNT162b, demonstrated approximately 94% to 95% efficacy in preventing COVID-19 with a favorable safety profile.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: